Lyndra Therapeutics Reports Results for Risperidone (LYN-005) in P-III Trial for the Treatment of Schizophrenia
Shots:
- The P-III (STARLYNG-1) study evaluates the safety, efficacy & PK of weekly LYN-005 (15 or 45mg) vs daily Risperdal (2 or 6mg) in patients (n=90) with schizophrenia & schizoaffective disorder
- The study met its 1EP of geometric mean ratio with one-sided Cmin of >0.80, one-sided Cmax of <1.25 & a two-sided Cavg of 0.80-1.40 & 2EPs for safety & PANSS score (to measure symptom severity in schizophrenia)
- The study shows that the effects of weekly LYN-005 & daily Risperdal are equivalent, confirming that Lyndra's LYNX drug delivery platform may offer a treatment choice that considerably lowers the frequency of doses. Additionally, Lyndra expects to initiate a (STARLYNG-2) study for its LYNX drug delivery platform by H2’24
Ref: Businesswire | Image: Lyndra
Related Post:- Teva and MedinCell Receive the US FDA’s Approval of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
